CN Patent

CN102060769B — 一种托伐普坦的制备方法

Assigned to Tianjin Institute of Pharmaceutical Research Co Ltd · Expires 2013-09-18 · 13y expired

What this patent protects

本发明涉及一种精氨酸血管加压素V2受体拮抗剂托伐普坦的制备方法。此制备方法可以高纯度、高收率的得到托伐普坦及其中间体，可以作为工业化方法加以大规模的生产。同时，减少了废液排放，有利于劳动保护，降低了生产成本，提高了经济效益。

USPTO Abstract

本发明涉及一种精氨酸血管加压素V2受体拮抗剂托伐普坦的制备方法。此制备方法可以高纯度、高收率的得到托伐普坦及其中间体，可以作为工业化方法加以大规模的生产。同时，减少了废液排放，有利于劳动保护，降低了生产成本，提高了经济效益。

Drugs covered by this patent

Patent Metadata

Patent number
CN102060769B
Jurisdiction
CN
Classification
—
Expires
2013-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.